Delisting riskPopularity #4,127
Lexaria Bioscience (LEXX)
Developer and licensor of DehydraTECH oral drug-delivery technology.
$3.36
After hours+0.17 (+5.33%)
At close$3.19(−6.86%)
In millions of USD, except per-share figures
| In millions | Q4 FY23Aug 2023 | Q1 FY24Nov 2023 | Q2 FY24Feb 2024 | Q3 FY24May 2024 | Q4 FY24Aug 2024 | Q1 FY25Nov 2024 | Q2 FY25Feb 2025 | Q3 FY25May 2025 | Q4 FY25Aug 2025 | Q1 FY26Nov 2025 | Q2 FY26Feb 2026 | Q3 FY26May 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 1 | 1 | 2 | 2 | 3 | 3 | 4 | 3 | 2 | 1 | 2 | |
| Research & development | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 3 | 2 | 1 | 0 | 1 |
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | |
| General & administrative | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Operating income | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before tax | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
| Net income | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
| EPS, basic | −$1.80 | −$1.95 | −$0.90 | −$1.95 | −$2.55 | −$2.40 | −$2.25 | −$3.15 | −$2.10 | −$1.12 | −$0.90 | −$1.20 |
| EPS, diluted | −$1.80 | −$1.95 | −$0.90 | −$1.95 | −$2.55 | −$2.40 | −$2.25 | −$3.15 | −$2.10 | −$1.12 | −$0.90 | −$1.20 |
| Weighted average shares, basic | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Weighted average shares, diluted | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| EBITDA | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −1 | −1 | −1 | −2 | −2 | −3 | −3 | −4 | −3 | −2 | −1 | −2 |
